Genetic screening of Russian Usher syndrome patients toward selection for gene therapy.
CONCLUSION: The Russian USH cohort shows both novel and known USH mutations. Clinically the prevalence of USH2 is low (39.28%) and the frequency of MYO7A mutations responsible for USH1B is very high (63.63%, N = 7/11) compared to other cohorts. These seven patients carrying MYO7A mutations are preliminarily eligible for the UshStat® gene therapy.
PMID: 30358468 [PubMed - as supplied by publisher]
Source: Ophthalmic Genetics - Category: Opthalmology Tags: Ophthalmic Genet Source Type: research
More News: Audiology | Deaf-Blind | Deafness | Eyes | Gene Therapy | Genetics | Opthalmology | Russia Health | Study | Usher Syndrome